Abstract
Abstract
Background
Prostate cancer is most often diagnosed at the metastatic stage in many sub-Saharan African countries. The objective of our study is to analyze the management of metastatic prostatic adenocarcinoma based on epidemiological, clinical, therapeutic and evolutionary aspects in developing country context.
Methods
Retrospective study collecting 276 patients from January 1st, 2012 to December 31st, 2019 in Aristide Le Dantec University Hospital in Dakar, Senegal. Parameters studied: age, family history of prostate cancer, reasons for consultation, total Prostate Specific Antigen (PSA), anatomic pathology examination, extension assessment, treatment, nadir PSA, castration resistance, and overall survival.
Results
The average age was 71.4 years. A family history of prostate cancer was noted in 21 patients. Spinal pain was the most noted reason for consultation. The average total PSA level was 1967.1 ng/ml. The majority of patients had moderately differentiated prostate cancer. Bone metastases were the most common. All patients had androgen suppression. A tumor cytoreduction was performed in 89 patients. The average nadir PSA was 193 ng/ml as early as the sixth month. The time to onset of castration resistance ranged from 6 to 30 months. Abiraterone acetate was used in seven patients and docetaxel in 43 patients. The overall survival of the patients was 19.8 ± 1.2 months.
Conclusion
Metastatic prostate cancer was most often symptomatic at the time of diagnosis. Second-line treatments were rarely used during castration resistance. Overall survival was low.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Fall B, Tengue K, Sow Y, Sarr A, Thiam A, Mohamed S et al (2012) Place de la pulpectomie bilatérale dans la suppression androgénique pour cancer de la prostate. Prog Urol 22:344–349
2. Diallo AB, Bah I, Barry AM, Dombeu NY, Barry M, Diallo MB (2008) Caractéristiques épidémiologiques du cancer de la prostate en Guinée. Afr J Urol 14(3):161–167
3. Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J et al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20(12):1730–1739
4. Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L et al (2020) French ccAFU guidelines-update 2020–2022: prostate cancer. Prog Urol 30:S136–S251
5. Laramas M, Costan C, Tessier A, Farneti D (2011) Cancer de prostate métastatique résistant à la castration: le point de vue de l’oncologue médical. Med Nucl 35(6):378–383
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献